Search Results for: Drug Development Delivery to Launch
Articles
Gerresheimer Launches Open Innovation Program for the Development of Home Therapy Solutions July 11, 2023
As an innovative system and solution provider, Gerresheimer is the global partner for the pharma and biotech industry. In collaboration with ekipa, a leading incubator for open innovation, Gerresheimer is calling on start-ups, companies, students, researchers, and….
Needle-Free Vaccine Delivery Platform Aims to End Frozen Storage Needs & Improve Access June 6, 2023
aVaxziPen’s innovative vaccine delivery platform aims to improve access to vaccines by removing the need for frozen storage and enabling easier distribution and deployment….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Putting Customers First June 5, 2023
Contributor Cindy H. Dubin speaks with several leading CDMOs from around the globe on their unique development and manufacturing capabilities and technologies, and presents real-world examples of how they have put these to use to produce innovative compounds, lower development costs, and shorten time to market.
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing & Supply Across Biologic Modalities June 5, 2023
Catalent recently announced it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic...Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell & Gene Therapy Development May 25, 2023
Catalent recently announced it has expanded the services and capabilities at its facility in Shiga, Japan, to include the storage,...BD Launches World's First Spectral Cell Sorter With High-Speed Cell Imaging May 18, 2023
BD (Becton, Dickinson and Company) recently announced the worldwide commercial launch of a new-to-world cell sorting instrument featuring two breakthrough...Sania Therapeutics Launches to Advance Novel Medicines for Neural Circuit Dysfunction May 17, 2023
Sania Therapeutics, focused on developing genetic medicines for neural circuit dysfunction, recently launched by unveiling its suite of proprietary patented platforms at….
SPECIAL FEATURE - Parenteral Drug Delivery: Could a Dose of AI Improve Development? May 1, 2023
Contributor Cindy H. Dubin speaks with several innovative companies to highlight the strides they are currently making toward improving dose accuracy, integrating design safety, and accelerating time to market.
DELIVERY DEVICES - Growing Connected Market Set to Elevate Healthcare Outcomes May 1, 2023
Michael Earl examines what the connected device market will look to achieve in the coming years and how it is likely to drive improved adherence to treatments and improve overall healthcare outcomes.
Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs March 29, 2023
Catalent recently announced the launch of the ProteoSuite Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into….
Catalent & Grünenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines March 15, 2023
Catalent and Grünenthal recently announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in...Catalent Expands UpTempo AAV Platform to Accelerate Development of Gene Therapies March 9, 2023
Catalent recently announced the expansion of its UpTempo platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors....FORMULATION FORUM - Changing the Landscape of Nanoparticles for Long-Acting Injectable Drugs March 1, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, say recently, there has been continued interest in parenteral NPs with sustained-release characteristics as more drugs discovered are poorly soluble and less bioavailable, and these challenges have led to enormous opportunities and launch of many drug products to market.
Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell & Gene Therapies January 24, 2023
Catalent recently announced the launch of its new Case Management Service, which has been specifically designed to address the unique...Ethicann & Catalent Sign Development & License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments January 12, 2023
Catalent and Ethicann Pharmaceuticals Inc. recently announced the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s….
Evonik Launches Plant-Based Squalene to Boost Vaccine Efficacy December 6, 2022
Evonik has recently launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth...Roivant & Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory & Fibrotic Diseases December 1, 2022
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis ….
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline November 3, 2022
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….
Syneos Health Expands Partnership With Datavant to Accelerate Delivery of New Therapies to Patients October 11, 2022
Syneos Health recently announced an expanded partnership with Datavant, the leader in helping organizations securely connect health data. The increasing collaboration between the companies will further leverage….
Nutriband & Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics for Aversa Fentanyl October 4, 2022
Nutriband Inc. and Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the company’s patented lead product, Aversa Fentanyl, an abuse-deterrent fentanyl transdermal system….
WEBINAR - 2024 Trends in Topical Drug Delivery: Insights & Innovation
This webinar will discuss some of the key trends from these leaders in the topical market on both a global and regional level, including the increased importance of sensory properties and the rise in non-conventional product formats, among others…..
